WebDisclosure WebDisclosure
Basculer en Français
10964 Companies
239972 Keywords
168740 Articles
129111 Press releases
Headlines Articles Press releases Mangoceuticals Inc. Remove
  1. Home
  2. Companies
  3. Mangoceuticals Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/22/2025 at 20:00, 1 year 4 months ago

    Mangoceuticals Inc.: Transforming Men's Wellness Through Innovative Solutions

    Innovation Telemedicine Men's Health Erectile Dysfunction Mangoceuticals
  • BRIEF

    published on 04/22/2025 at 20:00, 1 year 4 months ago

    Mangoceuticals Inc. : Transformer le bien-être masculin grâce à des solutions innovantes

    Innovation Télémédecine Mangoceuticals Santé Des Hommes Dysfonction Érectile
  • PRESS RELEASE

    published on 04/22/2025 at 19:55, 1 year 4 months ago

    CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

    Mangoceuticals Inc. introduces innovative men's health products through MangoRx, revolutionizing ED, testosterone therapy, hair restoration, and weight loss. CEO Jacob Cohen discusses the groundbreaking approach in an exclusive interview with Hawk Point Media
    Mangoceuticals Inc. MangoRx Men's Health Products Jacob Cohen Hawk Point Media
    Logo of Mangoceuticals Inc.
Accesswire
  • Published on 09/11/2026 at 04:00, 4 hours 7 minutes ago

    Torq Announces Debt Settlement and Corporate Update

  • Published on 09/10/2026 at 22:25, 9 hours 42 minutes ago

    Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer

  • Published on 09/10/2026 at 17:46, 14 hours 21 minutes ago

    Groete Access Road Nears Completion

  • Published on 09/10/2026 at 15:20, 16 hours 47 minutes ago

    MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026

  • Published on 09/10/2026 at 15:00, 17 hours 7 minutes ago

    All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE
EQS Group
  • Published on 09/11/2026 at 07:30, 36 minutes ago

    NAGRAVISION and MediaTek Broaden Partnership to Redefine Content Security for Premium Content on Connected TVs

  • Published on 09/11/2026 at 00:05, 8 hours 1 minute ago

    Club Offers for Travel Enthusiasts in Germany

  • Published on 09/11/2026 at 00:01, 8 hours 6 minutes ago

    Club Offers for Travel Enthusiasts in Germany

  • Published on 09/10/2026 at 22:39, 9 hours 27 minutes ago

    EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law

  • Published on 09/10/2026 at 22:10, 9 hours 56 minutes ago

    flatexDEGIRO with changes to the Supervisory Board

View all EQS
Les Echos
  • Published on 09/11/2026 at 07:00, 1 hour 7 minutes ago

    Transparantiekennisgeving van Baltisse Groep

  • Published on 09/11/2026 at 07:00, 1 hour 7 minutes ago

    Transparency notification by Baltisse Group

  • Published on 09/11/2026 at 07:00, 1 hour 7 minutes ago

    BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY

  • Published on 09/11/2026 at 07:00, 1 hour 7 minutes ago

    BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ

  • Published on 09/10/2026 at 19:30, 12 hours 37 minutes ago

    Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy